Ex vivo organ treatment with peg-phospholipid molecules

A PEG-, phospholipid technology, applied in application, preservation of human or animal body, urinary tract/kidney cells, etc., can solve problems such as hemodynamic instability, delayed graft function, impaired graft perfusion, etc.

Active Publication Date: 2021-06-29
ICOAT MEDICAL AB
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this phenomenon has also been observed in kidney and pancreas transplant recipients, who often suffer from hemodynamic instability immediately after reperfusion
Thus, a rapid decrease in systemic arterial pressure results in impaired graft perfusion and prolonged graft warm ischemia
These patients may suffer from delayed graft function, increased risk of rejection, and premature graft loss

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ex vivo organ treatment with peg-phospholipid molecules
  • Ex vivo organ treatment with peg-phospholipid molecules
  • Ex vivo organ treatment with peg-phospholipid molecules

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0037] The present invention relates generally to isolated organ treatments, and in particular to such isolated organ treatments capable of treating, inhibiting or preventing thrombotic inflammation (which precedes activation of the adaptive immune system) and hypotension induced by organ reperfusion.

[0038] The ex vivo methods of the present invention result in significant improvements in organ transplantation and organ handling by protectively shielding or coating the endothelial intima or endothelium and parenchyma of the vasculature of such organs or parts of such organs. This protective coating helps effectively protect against thrombotic inflammation as well as the deleterious effects of ischemia-reperfusion (I / R) injury (IRI).

[0039] The glycocalyx is essential to ensure microvascular hemostasis and prevent thrombotic inflammation. However, this glycocalyx is very sensitive to oxidative stress and ischemia-induced damage. Thus, during ischemia that occurs in associ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

An organ graft is ex vivo treated by ex vivo infusing a solution comprising PEG-phospholipid molecules into a vascular system of the organ graft. The solution comprising PEG-phospholipid molecules is ex vivo incubated in the vascular system to enable coating of at least a portion of the endothelial lining of the vascular system with the PEG-phospholipid molecules while keeping the organ or the part of the organ submerged in an organ preservation solution comprising PEG-phospholipid molecules. Such an ex vivo treatment of organ grafts with PEG-phospholipid protected the organ grafts against thromboinflammationand reduced blood pressure drops that otherwise occurred when reperfusing the organ graft in the recipient.

Description

technical field [0001] The present invention relates generally to isolated organ treatments, and in particular to such isolated organ treatments capable of inhibiting or preventing thrombotic inflammation and hypotension induced by organ reperfusion. Background technique [0002] Ischemia-reperfusion (I / R) injury (IRI) is a major contributor to the pathology of a variety of conditions, including transplantation, thrombotic disorders, sepsis, and cardiopulmonary bypass, all of which induce thrombotic inflammation. [0003] Kidney transplantation is by far the most effective treatment for patients with end-stage renal disease. Despite a dramatic improvement in treatment outcomes compared to its introduction in the 1960s, there is still 25% graft loss after 5 years and almost 50% graft loss after 10 years. The main goal for improving kidney transplantation outcomes is IRI, as IRI causes acute renal failure, delayed graft function, and distal organ failure. Immunosuppression d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A01N1/02
CPCA01N1/0226A01N1/021C12N5/0686
Inventor B·尼尔森K·尼尔森·埃克达尔M·詹森·韦恩Y·寺村A·贝格拉里安
Owner ICOAT MEDICAL AB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap